Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTERT peptide vaccine with imiquimod, low-dose cyclophosphamide, with or without celecoxib, in advanced cancer
ISRCTN07292674Phase 2Completed
- Sponsor
- Nottingham University Hospitals
- Start
- Feb 2013
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of hTERT peptide vaccine, Montanide ISA-51 VG, imiquimod, cyclophosphamide and celecoxib in cancer (2 arms), sponsored by Nottingham University Hospitals. Primary endpoints: Safety, tolerability and patient acceptability, Patient-reported acceptability and mood outcomes and 1 more. Started Feb 2013; status: completed.
02
Drugs
hTERT peptide vaccineMontanide ISA-51 VGimiquimodcyclophosphamidecelecoxib
03
Conditions
cancer
Beyond the preview
Go deeper on ISRCTN07292674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN07292674.